ProtoKinetix Inc. (PKTX.OB) Adds New Board Member

2/26/2015 11:52:08 AM

VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCQB:PKTX) (www.protokinetix.com) today announced that Peter K. Jensen, LL.B., BCL, B.Sc., Chairman of RepliCel Life Sciences and practicing lawyer, was appointed to the company's board of directors. The Company has also issued 1,000,000 shares of common stock of the Company and a three-year option for 1,000,000 shares of common stock exercisable at $0.05US per share to Mr. Jensen in connection with his appointment to the Board and for services to the Company.

Suggested Articles

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.

The agency was less likely to go against a recommendation when the panellists were united in their opinion.